mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.094 |
0.01 |
mRNA |
ML239 |
CTRPv2 |
pan-cancer |
AAC |
0.09 |
0.01 |
mRNA |
MP470 |
GDSC1000 |
pan-cancer |
AAC |
0.089 |
0.01 |
mRNA |
decitabine:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.079 |
0.01 |
mRNA |
vorinostat:navitoclax (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.088 |
0.01 |
mRNA |
OSI-027 |
CTRPv2 |
pan-cancer |
AAC |
-0.088 |
0.01 |
mRNA |
PX-12 |
CTRPv2 |
pan-cancer |
AAC |
0.07 |
0.01 |
mRNA |
BRD-K09587429 |
CTRPv2 |
pan-cancer |
AAC |
0.098 |
0.01 |
mRNA |
SB-431542 |
CTRPv2 |
pan-cancer |
AAC |
0.092 |
0.01 |
mRNA |
fulvestrant |
CTRPv2 |
pan-cancer |
AAC |
0.18 |
0.01 |